Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Research & Development (2021 - 2025)

Prime Medicine's Research & Development history spans 5 years, with the latest figure at $34.7 million for Q4 2025.

  • For Q4 2025, Research & Development rose 1.77% year-over-year to $34.7 million; the TTM value through Dec 2025 reached $160.6 million, up 3.44%, while the annual FY2025 figure was $160.6 million, 3.44% up from the prior year.
  • Research & Development reached $34.7 million in Q4 2025 per PRME's latest filing, down from $44.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $52.9 million in Q4 2021 to a low of $7.4 million in Q3 2021.
  • Average Research & Development over 5 years is $33.9 million, with a median of $36.2 million recorded in 2024.
  • The largest YoY upside for Research & Development was 238.47% in 2022 against a maximum downside of 45.05% in 2022.
  • A 5-year view of Research & Development shows it stood at $52.9 million in 2021, then tumbled by 45.05% to $29.1 million in 2022, then soared by 42.66% to $41.5 million in 2023, then fell by 17.74% to $34.1 million in 2024, then grew by 1.77% to $34.7 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Research & Development are $34.7 million (Q4 2025), $44.0 million (Q3 2025), and $41.4 million (Q2 2025).